Virtual screening and validation identifies the first reported inhibitors of HPPK.

HPPK, which directly precedes DHPS in the folate biosynthetic pathway, is a promising but chronically under-exploited anti-microbial target. Here we report the identification of new HPPK inhibitors, offering potential for new resistance circumventing therapies as well as avenues for diversifying the current HPPK inhibitor space.